Literature DB >> 23787064

An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene.

Gouji Toyokawa1, Mitsuhiro Takenoyama2, Kenichi Taguchi3, Ryo Toyozawa1, Eiko Inamasu1, Miyako Kojo1, Yoshimasa Shiraishi1, Yosuke Morodomi1, Tomoyoshi Takenaka1, Fumihiko Hirai1, Masafumi Yamaguchi1, Takashi Seto1, Mototsugu Shimokawa4, Yukito Ichinose1.   

Abstract

Anaplastic lymphoma kinase (ALK) fuses echinoderm microtubule-associated protein-like 4 (EML4) to acquire a transforming activity in lung adenocarcinomas. However, the presence of an EML4-ALK fusion gene in other lung cancer histologies is an extremely rare phenomenon. A 43-year-old female was referred to our department due to dyspnea on effort and left back pain. Computed tomography (CT) showed a large mass in the upper lobe of the left lung and a massive left pleural effusion, while a CT-guided needle biopsy confirmed a diagnosis of small-cell lung cancer (SCLC). Surprisingly, the tumor was genetically considered to harbor the EML4-ALK fusion gene (variant 2). Although the patient underwent two regimens of cytotoxic chemotherapy for SCLC, she died approximately seven months after the administration of first-line chemotherapy. Our analysis of 30 consecutive patients with SCLC for EML4-ALK revealed that two patients, including the current patient and a patient we previously reported, harbored the EML4-ALK fusion gene.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  EML4-ALK; Oncogenic driver mutation; Small-cell lung cancer

Mesh:

Substances:

Year:  2013        PMID: 23787064     DOI: 10.1016/j.lungcan.2013.05.022

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

1.  Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?

Authors:  Birgitta Hiddinga; Karen Zwaenepoel; Annelies Janssens; Jan Van Meerbeeck; Patrick Pauwels
Journal:  Oncotarget       Date:  2022-06-01

Review 2.  Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

Authors:  Rita Dorantes-Heredia; José Manuel Ruiz-Morales; Fernando Cano-García
Journal:  Transl Lung Cancer Res       Date:  2016-08

Review 3.  Treating ALK-positive non-small cell lung cancer.

Authors:  Dimitrios C Ziogas; Anna Tsiara; Georgios Tsironis; Maria Lykka; Michalis Liontos; Aristotelis Bamias; Meletios-Athanasios Dimopoulos
Journal:  Ann Transl Med       Date:  2018-04

Review 4.  Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.

Authors:  Till Plönes; Walburga Engel-Riedel; Erich Stoelben; Christina Limmroth; Oliver Schildgen; Verena Schildgen
Journal:  J Pers Med       Date:  2016-01-15

Review 5.  Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.

Authors:  Antonio Passaro; Chiara Lazzari; Niki Karachaliou; Gianluca Spitaleri; Alessia Pochesci; Chiara Catania; Rafael Rosell; Filippo de Marinis
Journal:  Onco Targets Ther       Date:  2016-10-17       Impact factor: 4.147

6.  Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor.

Authors:  Masayuki Nakajima; Naoki Uchiyama; Rie Shigemasa; Takeshi Matsumura; Ryota Matsuoka; Akihiro Nomura
Journal:  Intern Med       Date:  2016-11-01       Impact factor: 1.271

7.  Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung.

Authors:  Agnes Balla; Farrah Khan; Kenneth J Hampel; Dara L Aisner; Nikoletta Sidiropoulos
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-04-02

8.  ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature.

Authors:  Qiang Zheng; Mingjia Zheng; Yan Jin; Xuxia Shen; Ling Shan; Lei Shen; Yihua Sun; Haiquan Chen; Yuan Li
Journal:  Onco Targets Ther       Date:  2018-08-17       Impact factor: 4.147

9.  Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample.

Authors:  Dominic G Rothwell; Nigel Smith; Daniel Morris; Hui Sun Leong; Yaoyong Li; Antoine Hollebecque; Mahmood Ayub; Louise Carter; Jenny Antonello; Lynsey Franklin; Crispin Miller; Fiona Blackhall; Caroline Dive; Ged Brady
Journal:  Mol Oncol       Date:  2015-11-19       Impact factor: 6.603

10.  Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.

Authors:  Nobuyoshi Hayashi; Akihisa Fujita; Toyohiro Saikai; Hirotugu Takabatake; Mie Sotoshiro; Kyuutarou Sekine; Akihiko Kawana
Journal:  Intern Med       Date:  2017-11-20       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.